Trial Profile
A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Mapi Pharma
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 31 Mar 2022 According to a Mapi Pharma media release, data from this study will be presented at the forthcoming American Academy of Neurology annual meeting, 2022.
- 09 Aug 2021 Planned End Date changed from 1 Feb 2023 to 1 Nov 2024.